<DOC>
	<DOCNO>NCT03017313</DOCNO>
	<brief_summary>The purpose protocol , determine percentage patient initial LHRH prescription renew</brief_summary>
	<brief_title>To Evaluate Criteria Renewal Luteinizing Hormone-Releasing Hormone ( LHRH ) Analogue Treatment Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Adult men diagnose locally advanced metastatic prostate cancer schedule receive androgen deprivation therapy 3 6 month LHRH analogue include require neoadjuvant adjuvant androgen deprivation therapy association radiotherapy Patients provide write informed consent Patients mentally fit completing selfadministrated questionnaire Patients participate another clinical study time inclusion Patients another severe malignant disease Life expectancy le 12 month Patients already treat LHRH analogue within last year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>